RLAY Q3'26 Earnings: EPS estimate is (0.40) USD

What happened

Relay Therapeutics is scheduled to report its Q3 2026 results on November 4 after the market closes, with disclosure expected at 4:00 p.m. ET. The supplied estimates are revenue of 1.62 million USD and earnings per share, or EPS, of a 0.40 loss.

Confirmed

Global impact / market context

The report will show whether Relay’s revenue and per-share loss differ from the supplied estimates. A revenue shortfall could reduce cash available to fund operations, while a smaller-than-expected loss could ease concerns about spending; the article gives no results yet.

Analyst inference

The article lists estimated revenue of 1.62 million USD and an estimated 0.40 loss per share, alongside recent quarterly results that included revenue estimates and reported losses. These figures offer comparison points, but the article does not explain revenue sources or future funding needs.

Analyst inference

What to watch

1. Check the November 4 release for actual revenue against the 1.62 million USD estimate; the difference will show whether reported sales exceeded or missed expectations. Analyst inference
2. Compare reported EPS, meaning earnings or loss for each share, with the estimated 0.40 loss to gauge whether the quarterly loss was wider or narrower than expected. Analyst inference
3. Look for management comments on cash available and planned spending, if provided; those details could clarify whether operating costs may require changes to funding or development plans. Analyst inference

Evidence

• Original source link unavailable